Cambridge Biocapital · MHRA authorises orforglipron, a European first for GLP-1 tablets. Redx exits to Skye in $125m deal, relisting as Fibrx. Silence posts Phase 2 win in polycythemia vera. — Biotechnology newsletter ranking. Verify this listing to confirm the newsletter owner.
Confirm you publish Cambridge Biocapital. We'll email you a one-click verification link. Verifying is free and unlocks:
Know who really runs Cambridge Biocapital? Point us to them and we'll reach out to invite them to verify.